Stockreport

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome [Yahoo! Finance]

Ionis Pharmaceuticals, Inc.  (IONS) 
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ionispharma.com
PDF Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update at the FAST Global Science Summit in November CARLSBAD, Calif. Nov. 6, 2 [Read more]